Septerna (NASDAQ:SEPN - Get Free Report) had its price target lifted by equities research analysts at JPMorgan Chase & Co. from $48.00 to $51.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s target price would suggest a potential upside of 29.08% from the stock's current price.
Other equities research analysts also recently issued reports about the company. Wells Fargo & Company increased their price target on Septerna from $50.00 to $61.00 and gave the stock an "overweight" rating in a report on Wednesday, November 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Septerna in a research report on Thursday, October 15th. Wall Street Zen cut shares of Septerna from a "hold" rating to a "sell" rating in a report on Saturday, November 14th. Stifel Nicolaus boosted their price objective on shares of Septerna from $49.00 to $60.00 and gave the company a "buy" rating in a research report on Tuesday, November 10th. Finally, Raymond James Financial restated a "strong-buy" rating and issued a $49.00 target price on shares of Septerna in a research note on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.78.
Get Our Latest Stock Report on SEPN
Septerna Price Performance
NASDAQ SEPN traded up $0.06 during trading hours on Thursday, hitting $39.51. The company's stock had a trading volume of 72,438 shares, compared to its average volume of 368,761. Septerna has a 12 month low of $22.78 and a 12 month high of $53.34. The company's 50 day simple moving average is $40.64 and its two-hundred day simple moving average is $33.37. The company has a market cap of $1.88 billion, a P/E ratio of -30.96 and a beta of 2.20.
Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.15). Septerna had a negative net margin of 61.29% and a negative return on equity of 14.98%. The business had revenue of $18.88 million for the quarter, compared to the consensus estimate of $20.78 million. As a group, research analysts predict that Septerna will post -1.51 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Septerna news, CFO Gil M. Labrucherie sold 20,000 shares of the stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $41.62, for a total transaction of $832,400.00. Following the sale, the chief financial officer directly owned 20,000 shares in the company, valued at $832,400. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Alan Ezekowitz sold 81,820 shares of the firm's stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $48.09, for a total transaction of $3,934,723.80. Following the completion of the sale, the director directly owned 35,600 shares in the company, valued at approximately $1,712,004. This trade represents a 69.68% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 109,153 shares of company stock worth $5,042,851. Corporate insiders own 5.80% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the business. TRV GP V LLC acquired a new stake in Septerna in the second quarter valued at about $208,160,143. TRV GP VI LLC acquired a new position in Septerna during the 2nd quarter worth approximately $141,048,460. BlackRock Inc. purchased a new position in shares of Septerna during the 2nd quarter worth approximately $64,706,000. Jupiter Topco LLC acquired a new stake in shares of Septerna in the 2nd quarter valued at approximately $43,723,000. Finally, Primecap Management Co. CA acquired a new stake in shares of Septerna in the 2nd quarter valued at approximately $39,096,000.
Septerna Company Profile
(
Get Free Report)
Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.